Latest News about ABBV
Recent news which mentions ABBV
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
November 11, 2024
From Benzinga
AbbVie Shares Plunge as Experimental Schizophrenia Drug Flops in Trials
November 11, 2024
From Wall Street Pit
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
November 11, 2024
From Benzinga
3 Spectacular High-Yield Dividend Stocks to Buy in November
November 10, 2024
From Motley Fool
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
November 08, 2024
From Benzinga
2 Dividend Kings That Would Have Doubled Your Money in 5 Years
November 08, 2024
From Motley Fool
From Benzinga
Price Over Earnings Overview: AbbVie
November 01, 2024
From Benzinga
Market Analysis: AbbVie And Competitors In Biotechnology Industry
October 31, 2024
From Benzinga
From Motley Fool
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
From Benzinga
Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday?
October 30, 2024
From Benzinga
AbbVie Tops Q3 Expectations As Skyrizi, Rinvoq Drive Growth
October 30, 2024
From Benzinga
3 Dividend Growth Stocks to Buy and Never Sell
October 30, 2024
From Motley Fool
AbbVie Chart Reflects Bearish Signals Ahead Of Q3 Earnings
October 29, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.